Genentech announces replacement for retiring boss

16 December 2016

Genentech, the USA-based biotech unit of Swiss pharma giant Roche (ROG: SIX), has announced its new chief executive after the retirement of Ian Clark.

That man is Bill Anderson, who is also head of the company’s North American commercial operations and has served in a number of key leadership positions at Genentech and Roche over the past 10 years, most recently as head of global product strategy.

Mr Clark, aged 55, will step down at the end of 2016 after 14 years at Genentech, during which time the company merged with Roche in 2009. He drove the successful evolution of Genentech as part of a global organization and oversaw the launch of 15 new medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK